^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

chlorpromazine

Company:
Generic mfg.
Drug class:
DRD2 antagonist, DRD3 antagonist, DRD4 antagonist, Serotonin 1A-2A-2B-2C receptor antagonist
16d
Enrollment change
|
chlorpromazine
1m
Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells. (PubMed, Curr Issues Mol Biol)
Although FLT3 tyrosine kinase inhibitors (TKIs), such as quizartinib (Quiz) and gilteritinib, have improved clinical outcomes, secondary TKD mutations, particularly the gatekeeper mutation F691L, confer significant resistance. Expression of constitutively active STAT5 partially rescued CPZ-induced growth inhibition. These findings suggest that STAT5 suppression is a key mechanism of CPZ's antileukemic activity and support its potential as a therapeutic strategy for FLT3-ITD-positive AML.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
FLT3-ITD mutation • FLT3 mutation
|
Xospata (gilteritinib) • Vanflyta (quizartinib) • chlorpromazine
1m
Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA sequencing-based profiling of TP53. (PubMed, Oncoscience)
In this study, drug repurposing agent's metformin, chlorpromazine (CPZ) alone and combine were tested on both clinical and laboratory ovarian cancer samples to evaluate on hemocytometer and clonogenic assay for dead cell and proliferation respectively. The resulting data were analyzed to achieve successfully known target region and worked as a bridge between clinical and laboratory model. The insights gained from this study not only validate OVCAR3 as a representative model for HGSOC but also provide a foundation for developing targeted therapeutic strategies.
Journal
|
TP53 (Tumor protein P53)
|
TP53 wild-type
|
metformin • chlorpromazine
3ms
The Future of Oncology in Psychiatric Medications. (PubMed, J Clin Med)
The anticancer potential of psychiatric drugs seems to be extremely broad, and the most extensive anticancer literature has been reported on antidepressants (fluoxetine, amitriptyline, imipramine, mirtazapine, and St John's Wort) and antipsychotics (chlorpromazine, pimozide, thioridazine, and trifluoperazine)...Among antidementia drugs, memantine has documented anticancer effects, while there is limited evidence for galantamine. Of the new psychiatric substances, the antipsychotic drug brexpiprazole and the antidepressant vortioxetine have a very interesting body of literature regarding glioblastoma, based on in vitro and in vivo animal survival studies...The anticancer properties of psychiatric drugs may prove particularly useful in the period between chemotherapy and radiotherapy sessions to maintain the tumor-inhibitory effect. While further research is necessary to elucidate the mechanisms, clinical implications, dose-dependence of the effect, and clear guidelines for the use of psychiatric medications in cancer therapy, the potential for these commonly prescribed medications to contribute to cancer treatment enhances their value in the management of patients facing the dual challenges of mental health and cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SIRT1 (Sirtuin 1)
|
chlorpromazine • amitriptyline • fluoxetine • imipramine
4ms
The associations of suicidal ideation with psychopathology and inflammatory cytokines in patients with chronic schizophrenia. (PubMed, BMC Psychiatry)
There was higher overall risk of SI in patients with chronic schizophrenia. SI might be associated with psychotic symptoms, depression, insomnia, medication side effects, and increased levels of inflammatory cytokines. In clinical practice, doctors should take prompt preventive measures in patients combining suicidal risk factors.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta)
|
chlorpromazine
4ms
Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis. (PubMed, Adv Sci (Weinh))
In patient-derived xenograft (PDX) models, combined therapy of clathrin inhibitor (chlorpromazine) or SH3KBP1 silencing with sorafenib suppresses tumor growth and reduces microvascular density. This study demonstrates that CLTB promotes HCC progression through the NF-κB-PCLAF signaling axis and sEV-mediated vascular remodeling, providing a mechanistic foundation for developing combination therapies targeting CLTB.
Journal
|
PCNA (Proliferating cell nuclear antigen) • PCLAF (PCNA Clamp Associated Factor)
|
sorafenib • chlorpromazine
5ms
Toward pharmacologic therapy for glioblastoma: Identifying inhibitors of very long-chain acyl-CoA synthetase 3 (ACSVL3). (PubMed, bioRxiv)
These included drugs triflupromazine, phenazopyridine, chlorpromazine, emodin, and perphenazine which are approved for treating other conditions. Although secondary screening will likely exclude many or all of these, our findings support the notion that we have developed a viable method for detecting potential ACSVL3 inhibitors. Further characterization may reveal candidate pharmacologic agents for treatment of GBM and other cancers.
Journal
|
ACSL3 (Acyl-CoA Synthetase Long Chain Family Member 3)
|
chlorpromazine
9ms
R21NR016736: Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer (clinicaltrials.gov)
P2/3, N=70, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2025 --> Jun 2027
Trial completion date
|
chlorpromazine
9ms
METASENS: Explorations of the Normal Neural Behavioral and Pathological Bases of Metacognition (clinicaltrials.gov)
P=N/A, N=109, Completed, Versailles Hospital | Recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Mar 2025
Trial completion • Trial completion date • Trial primary completion date
|
chlorpromazine
10ms
Depressive and Negative Symptoms in the Early and Established Stages of Schizophrenia: Integrating Structural Brain Alterations, Cognitive Performance, and Plasma Interleukin 6 Levels. (PubMed, Biol Psychiatry Glob Open Sci)
We evaluated whether higher plasma interleukin 6 (IL-6) levels would be associated with more severe negative or depressive symptoms in schizophrenia and explored illness stage utilizing early (BeneMin [Benefit of Minocycline on Negative Symptoms of Psychosis: Extent and Mechanism], n = 201, 72.8% male) and established (iRELATE [Immune Response & Social Cognition in Schizophrenia], n = 94, 67.3% male) schizophrenia cohorts...All analyses were adjusted for sex, age, and chlorpromazine equivalent dose...Our results indicate that higher plasma IL-6 levels may be differently associated with the severity of depressive and negative symptoms dependent on the illness stage. Future work identifying elevated levels of inflammation in larger samples may allow stratification and personalized intervention by subgroups who are at risk of poor outcomes.
Journal
|
IL6 (Interleukin 6)
|
chlorpromazine • minocycline
1year
Managing Agitated Delirium with Neuroleptics and Anti-Epileptics As a Neuroleptic Sparing Strategy (clinicaltrials.gov)
P2/3, N=30, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=11 --> 30
Enrollment open • Enrollment change
|
chlorpromazine
1year
CHILL-1: Study on Hibernation-like Therapy Based on Mechanical Thrombectomy (clinicaltrials.gov)
P1, N=32, Recruiting, Capital Medical University | Not yet recruiting --> Recruiting
Enrollment open
|
chlorpromazine